Rivoceranib
- Generic Name
- Rivoceranib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C24H23N5O
- CAS Number
- 811803-05-1
- Unique Ingredient Identifier
- 5S371K6132
- Background
Rivoceranib is under investigation in clinical trial NCT02726854 (Apatinib as Second-line Treatment of Advanced Pancreatic Cancer).
- Indication
本品单药适用于既往至少接受过2种系统化疗后进展或复发的晚期胃腺癌或胃-食管结合部腺癌患者。患者接受治疗时应一般状况良好。
- Associated Conditions
- -
- Associated Therapies
- -
Apatinib, Irinotecan and S-1 (ApaIRIS) in Treating Patients With Metastatic Pancreatic Cancer After AG Regimen
- Conditions
- Interventions
- First Posted Date
- 2019-09-24
- Last Posted Date
- 2019-11-05
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 126
- Registration Number
- NCT04101929
- Locations
- 🇨🇳
Department of Pancreatic and Hepatobiliary Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University, Shanghai, Shanghai, China
A Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer (mCRC)
- Conditions
- Interventions
- First Posted Date
- 2019-08-29
- Last Posted Date
- 2024-05-02
- Lead Sponsor
- Elevar Therapeutics
- Target Recruit Count
- 29
- Registration Number
- NCT04073615
- Locations
- 🇺🇸
Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸Vanderbilt University School of Medicine, Nashville, Tennessee, United States
Camrelizumab /Apatinib for Recurrent Platinum-resistant Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2021-03-16
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 28
- Registration Number
- NCT04068974
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, China
Camrelizumab Combined With Apatinib in the Treatment of Patients With Advanced Gastric Cancer and Colorectal Cancer
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2020-09-29
- Lead Sponsor
- Zhongshan Hospital Xiamen University
- Target Recruit Count
- 62
- Registration Number
- NCT04067986
- Locations
- 🇨🇳
Zhongshan Hospital Affiliated to Xiamen University, Xiamen, Fujian, China
Camrelizumab Combined With Apatinib for Recurrent Resistant GTN
- Conditions
- Interventions
- First Posted Date
- 2019-08-06
- Last Posted Date
- 2021-07-30
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT04047017
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
SHR-1210 Plus Apatinib in Patients With Advanced-Stage Hepatocellular Carcinoma
- First Posted Date
- 2019-07-10
- Last Posted Date
- 2019-07-11
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT04014101
- Locations
- 🇨🇳
Zhongshan Hospital, Shanghai, Shanghai, China
Apatinib and Etoposide Capsule Versus Weekly Paclitaxel in Patients With Platinum Resistant Ovarian Cancer
- First Posted Date
- 2019-06-27
- Last Posted Date
- 2019-10-08
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 280
- Registration Number
- NCT04000295
- Locations
- 🇨🇳
Sun Yat-sen University, Guangzhou, Guangdong, China
Combination Neoadjuvant Chemotherapy With or Without Apatinib for HER2 Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-06-11
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 196
- Registration Number
- NCT03982485
- Locations
- 🇨🇳
Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China
Apatinib With Albumin-bound Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer
- First Posted Date
- 2019-05-08
- Last Posted Date
- 2019-05-08
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 35
- Registration Number
- NCT03942068
Apatinib in the Treatment of Recurrence or Metastasis of Esophageal Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-04-12
- Last Posted Date
- 2020-02-05
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 39
- Registration Number
- NCT03913182
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.